ArticleMedical hypothesis, discovery & innovation ophthalmology journal2012
Presbyopia: a new potential pharmacological treatment.
Article in Medical hypothesis, discovery & innovation ophthalmology journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac.Indian journal of ophthalmology · 2026Trial
- Trial
- Extract fromNutrients · 2024Trial
- The Science of Pseudoaccommodation and Its Therapeutic Potential.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Current Trends in Presbyopia Correction-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications.Journal of clinical medicine · 2025Article
- Pharmacological Treatment of Presbyopia Using Pilocarpine 1.25% Eye Drops.Journal of ophthalmic & vision research · 2024Article
- Pilocarpine in the Treatment of Presbyopia: Progress, Issues, and Future Prospects.Drugs & aging · 2024Review
- Effects of Miosis on the Visual Acuity Space under Varying Conditions of Contrast and Ambient Luminance in Presbyopia.Journal of clinical medicine · 2024Article
- Correction of presbyopia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Pharmacological treatment of presbyopia: A systematic review.European journal of translational myology · 2022Article
- Pharmacological Treatment in Presbyopia.Journal of clinical medicine · 2022Review
- A multicentric study of pharmacological treatment for presbyopia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Presbyopia Treatments by Mechanism of Action: A New Classification System Based on a Review of the Literature.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
- Pharmacological Therapy for Presbyopia in Patients with Previous Corneal Refractive Surgery: A Pilot Study.Ophthalmology and therapy · 2020Article
- Presbyopia Treatment With Eye Drops: An Eight Year Retrospective Study.Translational vision science & technology · 2020Article
- Optimization of the Light Sword Lens for Presbyopia Correction.Translational vision science & technology · 2020Article
- Near Vision Improvement with the Use of a New Topical Compound for Presbyopia Correction: A Prospective, Consecutive Interventional Non-Comparative Clinical Study.Ophthalmology and therapy · 2019Article
- Latanoprost could exacerbate the progression of presbyopia.PloS one · 2019Article
- Pharmacological treatments of presbyopia: a review of modern perspectives.Eye and vision (London, England) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presbyopia occurs after 40 years of age in humans with a progressive loss of accommodation. Accommodation depends on the contraction of the ciliary muscle and iris, lens changes and convergence. The parasympathetic system regulates the degree of ciliary muscle and iris contraction necessary to modify the shape and position of the lens and its stimulation is effective through the activation of muscarinic receptors that are present in both structures. The hypothesis proposed here suggests the correction of accommodation in emmetropic presbyopic patients using a pharmacological treatment that includes a cholinergic agent combined with non-steroidal anti-inflammatory drugs (NSAIDs). This drug combination can restore near vision without affecting distance vision. It is important to note that the pharmaceutical form used was devoid of any inflammatory or other collateral effects.
Indexed as
Identifiers
24600609PMC3939740W2111121795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.